Biocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company i...

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the...

Biocon Biologics plans to reduce its acquisition debt by $300 million over the next year. The company recently refinanced $1.1 billion in d...

Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...

Biocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...

The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...

Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...

Eris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations b...

The investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.

Adalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...

Eshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acqui...

"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build an...

To fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...

The transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...

Biocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...

Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to th...